Key Highlights
- Loss per share from continuing operations was USD 0.04, compared with USD 0.05.
- Net loss was USD 4.94 million, compared with Net Income of USD 50.49 million.
- Loss from operations was USD 1.64 million, compared with USD 2.06 million.
- Cash and cash equivalents were USD 580 thousand at September 30, 2026.
BeyondSpring (NASDAQ:BYSI) reported a net loss of USD 4.94 million for the third quarter of 2026, compared with net income of USD 50.49 million in the prior-year quarter. Loss per share from continuing operations was USD 0.04, compared with USD 0.05.
For the nine months ended September 30, 2026, the net loss was USD 8.42 million, compared with net income of USD 38.12 million.
Operating Results
Loss from operations was USD 1.64 million, compared with USD 2.06 million. Research and Development expenses were USD 968 thousand, compared with USD 1.11 million, and general and administrative expenses were USD 672 thousand, compared with USD 956 thousand.
For the nine months, loss from operations was USD 5.86 million, compared with USD 5.75 million.
Balance Sheet and Liquidity
Cash and cash equivalents were USD 580 thousand at September 30, 2026, compared with USD 2.97 million at December 31, 2025. Short-term investments were USD 1.00 million at December 31, 2025.
The filing states that the company had an accumulated Deficit of USD 360.65 million and net current liabilities of USD 3.33 million as of September 30, 2026.
Nasdaq Listing Notice
The filing states that on September 17, 2026, the company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC that the closing bid price of its ordinary shares had been below USD 1.00 per share for 30 consecutive Business days. The company has until March 16, 2027 to regain compliance with the bid price requirement and may be eligible for an additional 180-calendar-day compliance period, subject to the determination of the Nasdaq staff.
On September 29, 2026, the company entered into a sales agreement with Citizens JMP Securities, LLC to act as agent in selling up to 9,200,000 of its ordinary shares in an at-the-market offering program.
The filing states that in January 2025 the company entered into definitive agreements with three investors to sell a portion of the Series A-1 Preferred Shares of SEED Therapeutics Inc. Under those agreements, the third closing of 3,500,128 shares for approximately USD 14.88 million is scheduled to occur no later than December 15, 2026. The filing also states that on December 13, 2024, the Board of Directors approved a plan to divest approximately 90% to 100% of the company's interests in SEED.
For the nine months, research and development expenses were USD 2.67 million, compared with USD 3.07 million, and general and administrative expenses were USD 3.19 million, compared with USD 2.67 million. The filing also reports a net loss attributable to noncontrolling interests from discontinued operations of USD 3.40 million for the quarter, compared with USD 300 thousand.
BeyondSpring Q3 2026 Earnings: Key Takeaways
BeyondSpring reported a third quarter 2026 net loss of USD 4.94 million and a loss per share from continuing operations of USD 0.04. Cash and cash equivalents were USD 580 thousand at September 30, 2026.






Please wait processing your request...